Abstract
Nanotechnology has brought about the advent of personalized medicine in the era of targeted therapeutic strategies for cancer therapy. The ability to exploit tumor features for therapeutic gain has made it possible to manufacture more effective nanomedicines for cancer treatment. However, known obstacles, including the inability to overcome pathophysiological barriers of tumors, have impeded disease management. In spite of this, recent efforts have been made to develop more functionalized nanosystems that utilize the active-targeting approach. This article reviews the FDA-approved cancer drug delivery systems in the general framework of personalized nanomedicine. We discuss the latest efforts in the development of functionalized nano-systems, and summarize relevant ongoing preclinical and clinical trials.
Keywords: Personalized medicine, cancer therapy, drug delivery, nanoparticles, tumor-targeted nanomedicines, nanotechnology.
Graphical Abstract
Anti-Cancer Agents in Medicinal Chemistry
Title:Personalized Nanoparticles for Cancer Therapy: A Call for Greater Precision
Volume: 17 Issue: 8
Author(s): Nare Sahakyan, Amir Haddad, Shye Richardson, Valery Forcha-Etieundem, Lee Christopher, Hanan Alharbi and Robert Campbell*
Affiliation:
- Pharmaceutical Sciences, Massachusetts College of Pharmacy and Health Sciences, Department of Pharmaceutical Sciences, 19 Foster St. Worcester, MA 01608,United States
Keywords: Personalized medicine, cancer therapy, drug delivery, nanoparticles, tumor-targeted nanomedicines, nanotechnology.
Abstract: Nanotechnology has brought about the advent of personalized medicine in the era of targeted therapeutic strategies for cancer therapy. The ability to exploit tumor features for therapeutic gain has made it possible to manufacture more effective nanomedicines for cancer treatment. However, known obstacles, including the inability to overcome pathophysiological barriers of tumors, have impeded disease management. In spite of this, recent efforts have been made to develop more functionalized nanosystems that utilize the active-targeting approach. This article reviews the FDA-approved cancer drug delivery systems in the general framework of personalized nanomedicine. We discuss the latest efforts in the development of functionalized nano-systems, and summarize relevant ongoing preclinical and clinical trials.
Export Options
About this article
Cite this article as:
Sahakyan Nare, Haddad Amir, Richardson Shye, Forcha-Etieundem Valery, Christopher Lee, Alharbi Hanan and Campbell Robert*, Personalized Nanoparticles for Cancer Therapy: A Call for Greater Precision, Anti-Cancer Agents in Medicinal Chemistry 2017; 17 (8) . https://dx.doi.org/10.2174/1871520617666170102150730
DOI https://dx.doi.org/10.2174/1871520617666170102150730 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Natural Killer Cells Preferentially Target Cancer Stem Cells; Role of Monocytes in Protection Against NK Cell Mediated Lysis of Cancer Stem Cells
Current Drug Delivery The Structure and Function of Histone Deacetylases: The Target for Anti-cancer Therapy
Current Medicinal Chemistry Advances in Photodynamic Therapy of Cancer
Current Cancer Therapy Reviews How Does Alternaria alternata-Derived Alternariol Affect Our Health?
Mini-Reviews in Organic Chemistry Connexins as Precocious Markers and Molecular Targets for Chemical and Pharmacological Agents in Carcinogenesis
Current Medicinal Chemistry The Role of LncRNA TUG1 in Obesity-related Diseases
Mini-Reviews in Medicinal Chemistry A Comprehensive Review on miR-200c, A Promising Cancer Biomarker with Therapeutic Potential
Current Drug Targets The Return of the INGs, Histone Mark Sensors and Phospholipid Signaling Effectors
Current Drug Targets Luminescent Quantum Dots: A Very Attractive and Promising Tool in Biomedicine
Current Medicinal Chemistry Synthesis and Antioxidant Evaluation of a New Class of Thienopyrimidine-rhodanine Hybrids
Letters in Drug Design & Discovery Dietary Polyphenols for Prostate Cancer Therapy
Current Bioactive Compounds Orthotopic Liver Transplantation in Non-Alcoholic Fatty Liver Disease Patients
Reviews on Recent Clinical Trials Is Red Meat Required for the Prevention of Iron Deficiency Among Children and Adolescents?
Current Pediatric Reviews MSD-MAP: A Network-Based Systems Biology Platform for Predicting Disease-Metabolite Links
Combinatorial Chemistry & High Throughput Screening MicroRNAs as Early Biomarkers in Obesity and Related Metabolic and Cardiovascular Diseases
Current Pharmaceutical Design MIF and CD74 - Suitability as Clinical Biomarkers
Mini-Reviews in Medicinal Chemistry Novel Hybrid Compound 4-[(E)-2-phenylethenesulfonamido]-N-hydroxybutanamide with Antimetastatic and Cytotoxic Action: Synthesis and Anticancer Screening
Anti-Cancer Agents in Medicinal Chemistry Targeted Tumor Immunotherapy: Are Vaccines the Future of Cancer Treatment?
Current Drug Therapy Implication of Aberrant Glycosylation in Cancer and Use of Lectin for Cancer Biomarker Discovery
Protein & Peptide Letters Scaffold Vascularization: A Challenge for Three-Dimensional Tissue Engineering
Current Medicinal Chemistry